- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02163473
Hypoxia Inducible Factor 1 Alpha as a Novel Biomarker in Septic Shock
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Sepsis is one of the most significant challenges in critical care. Septic shock (SS) is the most severe form of sepsis and is associated with higher mortality, significant financial expenses and longer lengths of stay. Pathophysiological mechanisms of SS include 3 key components: 1) bacterial overgrowth, 2) spill of bacterial product into the blood causing hemodynamic insufficiency, and 3) both lead to tissue hypoxia (TH). To date the biomarkers of sepsis/SS are limited to hemodynamic parameters. However, aggressive fluid resuscitation does not fully prevent development of tissue hypoxia (TH). To date the investigators are limited in appreciating TH by measurement of lactic acid (LA), which is neither an early nor an accurate marker. Unfortunately, LA has limited predictive value in SS due to its complex metabolism. Thus, there is an acute need for biomarkers that would aid diagnosis and prognosis of sepsis/septic shock.
Cellular responses/adaptations to hypoxia rely on the transcription hypoxia-inducible factor HIF, a heterodimeric protein composed of a constitutively expressed subunit and an inducible (types 1, 2, and 3) subunit. More recently HIF was identified in diverse tissues including blood; it has been also shown that HIF expression in blood cells is representative of systemic tissues in hypoxic conditions.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32610
- University of Florida
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria: Septic patients
- Age 18 ≤ 80 years
- Negative pregnancy test for women of childbearing potential
- Meets two or more of Systemic Inflammatory Response System (SIRS) criteria (tachypnea, tachycardia, hypo/hyperthermia, leukopenia/leukocytosis)
- Evidence of tissue hypo-perfusion, or organ dysfunction by any of the following
- Sepsis induced hypotension with systolic blood pressure <90
- Lactate above 1.5 mmol/Liter
- Urine output below 0.5 mL/kg/hr for more than 2 hours despite adequate fluid resuscitation
- Tissue hypoxia
- Bilirubin > 2 mg/dl in absence of liver cirrhosis
- Creatinine (CR)> 2.0 mg/dL, Acute Kidney Injury as evident by CR increase by 0.5 mg/dL from baseline
- Platelet count < 100,000
- Coagulopathy with international normalized ratio (INR) >1.5
Inclusion: Healthy Controls
- Age and gender-matched to sepsis patients
- Negative pregnancy test in women of childbearing potential
- Never smoker (<1 pack year history)
Exclusion Criteria: Septic patients
- History of Malignancy, including carcinoma during the preceding 5 years.
- Recent surgery, within 48 hours, or anticipated surgery within 24 hours
- Contraindication for neck/chest central venous line
- History of cardiopulmonary resuscitation (CPR) prior to inclusion
- Transfer from another institution
- History of cirrhosis
- Transplant recipient
- Known HIV
- Use of ≥ 15 mg prednisone daily or equivalent
- Severe anemia: hematocrit ≤ 20
Exclusion: Healthy Controls
- History of Malignancy, including carcinoma during the preceding 5 years.
- Taking any prescription medications, other than any type of prescribed hormonal birth control.
- Current smoking history and/or > 1 pack year history
- Current use (within the last week) anti-inflammatory medications, such as aspirin, ibuprofen, naproxen and/or prednisone
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Septic patients
Blood Draw Biological samples: The investigators will collect blood and compare the expression of HIF complex in 3 distinct ways: between patients and controls, within the same patient in a time-dependent fashion, and between different patients.
|
The investigators will draw two sets of blood samples.
One at baseline, 10 mL, and another, 24 hours later, 10 mL, for a total of 20 mL.
|
Healthy Control
The investigators will collect blood and compare the expression of HIF complex in 3 distinct ways: between patients and controls, within the same patient in a time-dependent fashion, and between different patients.
|
The investigators will draw 10 mL, once, during baseline for a total of 10 mL among the healthy control group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hypoxia-inducible factor as a predictive biomarker of sepsis.
Time Frame: Baseline,
|
Hypoxia-inducible factor will be measured at initial diagnosis (baseline) and 24 hours later in subjects with clinical presentation of sepsis and correlated with lactic acidosis.
|
Baseline,
|
Hypoxia-inducible factor as a predictive biomarker of sepsis
Time Frame: 24 hours
|
Hypoxia-inducible factor will be measured at initial diagnosis (baseline) and 24 hours later in subjects with clinical presentation of sepsis and correlated with lactic acidosis.
|
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the role of HIF complex as biomarker and its correlation with "Survive the Sepsis Campaign 2012" gold standard septic shock severity and morbidity/mortality predictors.
Time Frame: 28 days
|
At discharge a detailed chart analysis will be performed for the first 24 hrs, survival at 28 day; correlations of clinical course-derived data and serum cytokine content with the HIF content/expression and function will be analyzed by Spearman's rank correlation test.
|
28 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Wael Nasser, MD, University of Florida
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB201200142
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sepsis
-
University of Kansas Medical CenterUniversity of KansasRecruitingSepsis | Septic Shock | Sepsis Syndrome | Sepsis, Severe | Sepsis Bacterial | Sepsis BacteremiaUnited States
-
Jip GroenInBiomeRecruitingMicrobial Colonization | Neonatal Infection | Neonatal Sepsis, Early-Onset | Microbial Disease | Clinical Sepsis | Culture Negative Neonatal Sepsis | Neonatal Sepsis, Late-Onset | Culture Positive Neonatal SepsisNetherlands
-
Karolinska InstitutetÖrebro University, SwedenCompletedSepsis | Sepsis Syndrome | Sepsis, SevereSweden
-
The University of QueenslandRoyal Brisbane and Women's HospitalUnknown
-
Ohio State UniversityCompletedSepsis, Severe Sepsis and Septic ShockUnited States
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
Beckman Coulter, Inc.Biomedical Advanced Research and Development AuthorityRecruitingSevere Sepsis | Severe Sepsis Without Septic ShockUnited States
-
University of LeicesterUniversity Hospitals, Leicester; The Royal College of AnaesthetistsCompletedSepsis | Septic Shock | Severe Sepsis | Sepsis SyndromeUnited Kingdom
-
Zagazig UniversityRecruitingSepsis-associated EncephalopathyEgypt
-
Weill Medical College of Cornell UniversityNational Heart, Lung, and Blood Institute (NHLBI); New York Presbyterian Hospital and other collaboratorsCompletedSepsis | Septic Shock | Severe Sepsis | Infection | Sepsis SyndromeUnited States
Clinical Trials on Septic patients
-
Cantonal Hospital ZenicaCompletedSepsis | Septic Shock | Coagulation Disorder | COVID 19 Associated CoagulopathyBosnia and Herzegovina
-
University Hospital, Strasbourg, FranceActive, not recruiting
-
University Hospital, RouenUnknown
-
University Hospital, LimogesCompleted
-
Rigshospitalet, DenmarkUniversity of CopenhagenSuspendedSepsis | Delirium | Septic EncephalopathyDenmark
-
Pontificia Universidad Catolica de ChileErasmus Medical Center; Hospital do Coracao; Fundacion Clinica Valle del LiliRecruiting
-
Hospices Civils de LyonCompletedPseudoarthrosis of BoneFrance
-
University of Colorado, DenverAgency for Healthcare Research and Quality (AHRQ)CompletedSepsis | Emergencies | Septic ShockUnited States
-
Assiut UniversityNot yet recruiting
-
Centre Hospitalier Universitaire, AmiensUnknown